Company Profile
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Latest News
PINK vs. XLV: How Do These Two Health Care ETFs Match Up?
Fed Meeting, Inflation, Boeing, Meta, Apple, Exxon, and More to Watch This Week
Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.abbvie.com |
| Audit Risk | 6 |
| Board Risk | 5 |
| Overall Risk | 7 |
| Market Cap | 458.24B |
| Trailing P/E | 126.52 |
| Forward P/E | 15.92 |
| Dividend Rate | 6.92 |
| Dividend Yield | 2.69% |
| Trailing Annual Div. Rate | 6.74 |
| Trailing Annual Div. Yield | 2.62% |
| Trailing EPS | 2.05 |
| Forward EPS | 16.29 |
| Book Value | -3.77 |
| Enterprise-to-Revenue | 8.31 |
| Enterprise-to-EBITDA | 17.44 |
| Short Ratio | 2.42 |
| Ex-Dividend Date | 07/15/2026 |
| Dividend Date | 08/14/2026 |
| Earnings Date | 07/31/2026 |
| Earnings Call Date | 07/31/2026 |
| Earnings Average | 3.63 |
| Earnings Low | 3.57 |
| Earnings High | 3.81 |
| Revenue Average | 16.77B |
| Revenue Low | 16.47B |
| Revenue High | 16.98B |